Opposite to eye diseases, whereby vascular permeability is considered a valid therapeutic target only when inhibited, a few teams have proposed to exploit NRP1 pro-permeability properties to promote penetration of co-injected anti-cancer drugs and develop more efficient delivery systems [131,132]. The gene discussed is NRP1; the disease is eye disorder.